AAVantgarde Bio
Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease
- Location
- —
- Roles tracked
- 0
- In pipeline
- 0
- Tracking since
- —
At a glance
You're tracking 0 roles at AAVantgarde Bio. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync- Industry
- Biotechnology Research
- Company size
- 75 people
- Type
- Privately Held
- Total funding
- $206.3M
AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients.
Gene Therapy
Ophthalmology
and Rare diseases
